Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care
- Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.
- Collaboration with PathAI expands pathologist access to innovative AI-powered technology to support companion diagnostic and drug development programs.
- Builds on Roche’s Digital Pathology Open Environment, expanding the company’s commitment to improving patient outcomes and advancing personalised healthcare through innovation
Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology. Under the development and distribution agreement, the companies will jointly develop an embedded image analysis workflow for pathologists. This workflow will allow PathAI image analysis algorithms to be accessed within NAVIFY Digital Pathology, the cloud version of Roche’s uPath enterprise software. This collaboration is now possible through Roche’s Digital Pathology Open Environment, which allows pathologists to securely access third-party AI-powered technology alongside Roche’s growing menu of AI-based image analysis tools.
This agreement with PathAI is among the first to expand digital tools through the Roche open environment, and is one of the first for PathAI to distribute its AI-powered solutions via a third party platform.
“Working together, Roche and PathAI will bring the latest leading technologies to pathologists through our digital pathology solution. Expanded access to a menu of high medical value digital diagnostic tools will further ensure that patients are accurately diagnosed and receive the most effective treatment available,” said Thomas Schinecker, CEO Roche Diagnostics.
Roche will initially distribute PathAI-developed research-use-only (RUO) algorithms through NAVIFY Digital Pathology, spanning multiple cancer types. The combined innovation will expand support for healthcare companies’ companion diagnostic and drug development programs.
“This collaboration brings together all of the components required to deliver and commercialise a differentiated AI-based digital pathology medical device including assay, scanner, image management system and algorithm. We believe this partnership will unlock the potential for digital pathology in the companion diagnostics setting, offering a differentiated service to biopharma sponsors and ultimately new opportunities to improve patient outcomes,” said Dr. Andy Beck, CEO of PathAI.
About Roche Digital Pathology
As the leading provider of pathology lab solutions, Roche is delivering an end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated clinical image analysis algorithms.
Whole slide imaging combined with modern artificial intelligence (AI)-based image analysis tools have the potential to transform the practice of pathology. The use of AI and deep learning methods to interpret whole slide images in digital pathology enables pathologists to derive novel and meaningful diagnostic insights from tissue samples. AI-based image analysis automates quantitative tasks and enables fast, repeatable evaluation of information-rich tissue images that are sometimes difficult to interpret manually. AI-based image analysis uncovers aspects that are invisible to the human eye and reduces the risk of human error. Patients, whose tissue samples are analysed using AI-based image analysis, can benefit from a faster and more accurate diagnosis. The insights gained from these analyses can help pathologists determine the best treatment option for cancer patients.
Roche offers two deployment options for its uPath software: an on-premise solution and a cloud solution, marketed as NAVIFY Digital Pathology. The VENTANA DP 200 slide scanner and Roche uPath enterprise software are CE-IVD marked for in-vitro diagnostic use and are available in the U.S. for research use only (RUO). Image analysis algorithms developed by third-party entities and their utilisation are the responsibility of the third party provider.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Dr. Nicolas Dunant Phone: +41 61 687 05 17 | Patrick Barth Phone: +41 61 688 44 86 |
Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 | Karsten Kleine Phone: +41 61 682 28 31 |
Nina Mählitz Phone: +41 79 327 54 74 Sileia Urech Phone: +41 79 935 81 48 | Nathalie Meetz Phone: +41 61 687 43 05 |
Roche Investor Relations | |
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com | Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com |
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com | Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
Investor Relations North America | |
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Orion Group Interim Report January–March 202425.4.2024 11:00:00 CEST | Press release
ORION CORPORATION INTERIM REPORT 1-3/2024 25 APRIL 2024 at 12:00 EEST Orion Group Interim Report January–March 2024 Net sales totalled EUR 308.5 (January–March 2023: 277.9) million Operating profit was EUR 56.0 (55.5) millionBasic earnings per share were EUR 0.31 (0.31)Cash flow from operating activities per share was EUR 0.78 (0.03) The outlook for 2024 has been specified regarding operating profit: Operating profit is estimated to be EUR 280 million to EUR 310 million. Previously operating profit was estimated to be EUR 270 million to EUR 310 million. Key figures 1-3/241-3/23Change %1-12/23 Net sales, EUR million 308.5 277.9 +11.0% 1,189.7 EBITDA, EUR million 68.5 67.7 1.2% 326.4 % of net sales 22.2% 24.4% 27.4% Operating profit, EUR million 56.0 55.5 +1.0% 274.9 % of net sales 18.2% 20.0% 23.1% Profit before taxes, EUR million 54.9 55.1 -0.4% 271.9 % of net sales 17.8% 19.8% 22.9% Profit for the period, EUR million 43.8 43.8 -0.1% 216.8 % of net sales 14.2% 15.8% 18.2% Research and
Delårsrapport 1. kvartal 202425.4.2024 10:48:56 CEST | pressemeddelelse
Vedlagt følger delårsrapport for 1. kvartal 2024 for DLR Kredit A/S. Vedhæftet fil DLR Kredit delårsrapport 1. kvartal 2024
Correction: DOVRE GROUP TRADING STATEMENT JANUARY 1 – MARCH 31, 202425.4.2024 10:45:00 CEST | Press release
Dovre Group Plc Stock exchange release April 25, 2024, at 9.15 a.m. DOVRE GROUP TRADING STATEMENT JANUARY 1 – MARCH 31, 2024 Significant write-down of a single renewable project led to a negative operating profit Correction: PDF attachments have been added. Dovre Group Plc issues today a trading statement for the three months ended on March 31, 2024.The figures presented in this trading statement are not audited. Last year’s corresponding period in parentheses. January – March 2024 Net sales EUR 42.3 (45.8) million – decrease 7.6% Project Personnel: net sales EUR 25.2 (24.8) million – increase 1.7%Consulting: net sales EUR 3.6 (5.1) million – decrease 29.6%Renewable Energy: net sales EUR 13.5 (15.9) million - decrease 15.1%EBITDA EUR -4.6 (1.9) million Operating result EUR -4.9 (1.7) million Result before tax EUR -5.1 (1.5) million Result for the shareholders of the parent company EUR -2.4 (1.0) millionEarnings per share EUR -0.023 (0.010) Net cash flow from operating activities EUR -1
IBFD Travel Grant Opens Doors for International Tax Law Researchers25.4.2024 10:00:00 CEST | Press release
IBFD is excited to announce the opening of applications for its third annual Travel Grant for International Tax Law Research. This prestigious grant aims to support students worldwide who are conducting research in tax law, international tax law or tax history AMSTERDAM, April 25, 2024 (GLOBE NEWSWIRE) -- Recognizing the financial challenges associated with travel and accommodation, IBFD is committed to bridging the gap and providing students with unique research opportunities. “We understand the financial burden that students face when it comes to accessing resources and networking with experts,” says Belema R. Obuoforibo, Director of the IBFD Knowledge Centre and Executive Board Member. “Through this grant, we aim to open doors for a wider range of students, enabling them to benefit from our library’s exceptional resources and connect with our esteemed tax law experts.” The IBFD Travel Grant is open to undergraduate, graduate and postgraduate students from any country. While the exac
Trakx launches a new product: Trakx USDc Earn CTI powered by OpenTrade25.4.2024 10:00:00 CEST | Press release
Paris, 25 April 2024, 10:00AM CET: Trakx, an emerging global fintech company providing thematic Crypto Tradable Indices (“CTIs”), today announced the launch of the Trakx USDc Earn CTI powered by OpenTrade that is designed to allow users to easily generate high risk-adjusted returns on their USDc backed by US Treasury Bill yields. With the USDc Earn CTI, Trakx offers a unique instrument that seamlessly earns US Treasury Bills (T-Bills) like returns, while the assets are securely managed through OpenTrade’s bankruptcy remote structure. USDc holders on Trakx can now maximize the value of their USDC holdings by investing in Trakx USDc Earn CTI to earn stable, predictable yield, backed by real world financial assets, all through the existing Trakx interface.The product will be available as a standard CTI on the Trakx platform but can also be customised based on specific needs and requirements. Trakx’s partnership with OpenTrade is a case study in how France is emerging as a regional hub for